Rice Hall James & Associates LLC Buys New Stake in MaxCyte, Inc. (NASDAQ:MXCT)

Rice Hall James & Associates LLC bought a new stake in shares of MaxCyte, Inc. (NASDAQ:MXCT) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 263,833 shares of the company’s stock, valued at approximately $1,098,000.

Several other institutional investors also recently bought and sold shares of the stock. Valmark Advisers Inc. grew its stake in MaxCyte by 2.2% during the fourth quarter. Valmark Advisers Inc. now owns 115,654 shares of the company’s stock valued at $481,000 after acquiring an additional 2,478 shares in the last quarter. Rhumbline Advisers grew its stake in shares of MaxCyte by 1.6% in the 4th quarter. Rhumbline Advisers now owns 153,655 shares of the company’s stock worth $639,000 after buying an additional 2,402 shares in the last quarter. Chevy Chase Trust Holdings LLC grew its stake in shares of MaxCyte by 0.6% in the 4th quarter. Chevy Chase Trust Holdings LLC now owns 1,339,829 shares of the company’s stock worth $5,574,000 after buying an additional 7,781 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of MaxCyte by 10.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 22,366 shares of the company’s stock worth $93,000 after buying an additional 2,154 shares in the last quarter. Finally, Gagnon Securities LLC grew its stake in shares of MaxCyte by 234.1% in the 4th quarter. Gagnon Securities LLC now owns 197,326 shares of the company’s stock worth $821,000 after buying an additional 138,257 shares in the last quarter. 68.81% of the stock is owned by hedge funds and other institutional investors.

MaxCyte Price Performance

Shares of NASDAQ:MXCT opened at $4.03 on Wednesday. MaxCyte, Inc. has a 52 week low of $3.16 and a 52 week high of $5.26. The firm has a fifty day simple moving average of $4.42 and a two-hundred day simple moving average of $4.05.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.